• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

生化和结构分析表明,纤溶酶原激活物与其同源蛋白底物和抑制剂是共同进化的。

Biochemical and structural analyses suggest that plasminogen activators coevolved with their cognate protein substrates and inhibitors.

机构信息

From the Department of Molecular Biology and Genetics, Aarhus University, 8000 Aarhus, Denmark and.

the School of Biological Sciences, University of Manchester, M13 9PL Manchester, United Kingdom.

出版信息

J Biol Chem. 2019 Mar 8;294(10):3794-3805. doi: 10.1074/jbc.RA118.005419. Epub 2019 Jan 16.

DOI:10.1074/jbc.RA118.005419
PMID:30651349
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6416416/
Abstract

Protein sequences of members of the plasminogen activation system are present throughout the entire vertebrate phylum. This important and well-described proteolytic cascade is governed by numerous protease-substrate and protease-inhibitor interactions whose conservation is crucial to maintaining unchanged protein function throughout evolution. The pressure to preserve protein-protein interactions may lead to either co-conservation or covariation of binding interfaces. Here, we combined covariation analysis and structure-based prediction to analyze the binding interfaces of urokinase (uPA):plasminogen activator inhibitor-1 (PAI-1) and uPA:plasminogen complexes. We detected correlated variation between the S3-pocket-lining residues of uPA and the P3 residue of both PAI-1 and plasminogen. These residues are known to form numerous polar interactions in the human uPA:PAI-1 Michaelis complex. To test the effect of mutations that correlate with each other and have occurred during mammalian diversification on protein-protein interactions, we produced uPA, PAI-1, and plasminogen from human and zebrafish to represent mammalian and nonmammalian orthologs. Using single amino acid point substitutions in these proteins, we found that the binding interfaces of uPA:plasminogen and uPA:PAI-1 may have coevolved to maintain tight interactions. Moreover, we conclude that although the interaction areas between protease-substrate and protease-inhibitor are shared, the two interactions are mechanistically different. Compared with a protease cleaving its natural substrate, the interaction between a protease and its inhibitor is more complex and involves a more fine-tuned mechanism. Understanding the effects of evolution on specific protein interactions may help further pharmacological interventions of the plasminogen activation system and other proteolytic systems.

摘要

纤溶酶原激活系统成员的蛋白序列存在于整个脊椎动物门。这个重要且描述完善的蛋白水解级联受到许多蛋白酶-底物和蛋白酶-抑制剂相互作用的调控,其保守性对于维持蛋白功能在进化过程中不变至关重要。为了保持蛋白-蛋白相互作用的压力可能导致结合界面的共同保守或共变。在这里,我们结合共变分析和基于结构的预测来分析尿激酶(uPA):纤溶酶原激活物抑制剂-1(PAI-1)和 uPA:纤溶酶原复合物的结合界面。我们检测到 uPA 的 S3 口袋衬里残基与 PAI-1 和纤溶酶原的 P3 残基之间存在相关的变化。这些残基已知在人 uPA:PAI-1 米氏复合物中形成许多极性相互作用。为了测试在哺乳动物多样化过程中相互关联且发生的突变对蛋白-蛋白相互作用的影响,我们从人类和斑马鱼中产生 uPA、PAI-1 和纤溶酶原,以代表哺乳动物和非哺乳动物的同源物。使用这些蛋白中的单个氨基酸点取代,我们发现 uPA:纤溶酶原和 uPA:PAI-1 的结合界面可能共同进化以保持紧密的相互作用。此外,我们得出结论,尽管蛋白酶-底物和蛋白酶-抑制剂之间的相互作用区域是共享的,但这两种相互作用在机制上是不同的。与蛋白酶切割其天然底物相比,蛋白酶与其抑制剂的相互作用更复杂,涉及更精细的机制。了解进化对特定蛋白相互作用的影响可能有助于进一步干预纤溶酶原激活系统和其他蛋白水解系统的药理学。

相似文献

1
Biochemical and structural analyses suggest that plasminogen activators coevolved with their cognate protein substrates and inhibitors.生化和结构分析表明,纤溶酶原激活物与其同源蛋白底物和抑制剂是共同进化的。
J Biol Chem. 2019 Mar 8;294(10):3794-3805. doi: 10.1074/jbc.RA118.005419. Epub 2019 Jan 16.
2
Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.通过定点诱变确定尿激酶型纤溶酶原激活剂-纤溶酶原激活剂抑制剂-1复合物与低密度脂蛋白受体家族内吞作用受体的结合区域。
FEBS J. 2006 Nov;273(22):5143-59. doi: 10.1111/j.1742-4658.2006.05511.x. Epub 2006 Oct 17.
3
Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.尿激酶型纤溶酶原激活物-纤溶酶原激活物抑制剂-1复合物与内吞作用受体α2-巨球蛋白受体/低密度脂蛋白受体相关蛋白及极低密度脂蛋白受体的结合涉及抑制剂中的碱性残基。
Biochem J. 1998 Jan 1;329 ( Pt 1)(Pt 1):55-63. doi: 10.1042/bj3290055.
4
Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.活性中心环构象和动力学变化揭示了纤溶酶原激活物抑制剂-1(PAI-1)与纤溶酶原激活物及玻连蛋白形成的不同结合复合物。
Protein Sci. 2016 Feb;25(2):499-510. doi: 10.1002/pro.2841. Epub 2015 Dec 2.
5
A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.丝氨酸蛋白酶抑制剂诱导尿激酶型纤溶酶原激活剂产生广泛的蛋白水解敏感性,这表明在丝氨酸蛋白酶抑制剂的抑制机制中,蛋白酶底物结合口袋和氧阴离子洞发生了扭曲。
Eur J Biochem. 2001 Feb;268(3):673-85. doi: 10.1046/j.1432-1327.2001.01921.x.
6
Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1.将RRHR基序引入鸡尿激酶型纤溶酶原激活剂(ch-uPA)可使其对纤溶酶原激活剂抑制剂(PAI)-1和PAI-2敏感,并使ch-uPA介导的细胞外基质降解受PAI-1控制。
Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):2933-8. doi: 10.1073/pnas.94.7.2933.
7
Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.低密度脂蛋白受体相关蛋白中尿激酶型纤溶酶原激活物-纤溶酶原激活物抑制剂-1复合物双结构域结合位点的分析
Biochem J. 2001 Jul 1;357(Pt 1):289-96. doi: 10.1042/0264-6021:3570289.
8
A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.由半胱氨酸突变产生的新型纤溶酶原激活物抑制剂延长了其半衰期:与癌症和血管生成的相关性。
Mol Cancer Ther. 2003 Jan;2(1):19-28.
9
Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.大鼠肝纤维化形成过程中纤溶酶原激活物及纤溶酶原激活物抑制剂表达增加:星状细胞的作用
J Hepatol. 1999 Oct;31(4):703-11. doi: 10.1016/s0168-8278(99)80351-1.
10
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.受体结合型尿激酶对1型纤溶酶原激活物抑制剂的可及性
Proc Natl Acad Sci U S A. 1989 Jul;86(13):4828-32. doi: 10.1073/pnas.86.13.4828.

引用本文的文献

1
High-throughput amino acid-level characterization of the interactions of plasminogen activator inhibitor-1 with variably divergent proteases.纤溶酶原激活物抑制剂-1与可变差异蛋白酶相互作用的高通量氨基酸水平表征
Protein Sci. 2025 Apr;34(4):e70088. doi: 10.1002/pro.70088.
2
Between Protein Fold and Nucleophile Identity: Multiscale Modeling of the TEV Protease Enzyme-Substrate Complex.蛋白质折叠与亲核试剂特性之间的关系:TEV蛋白酶-底物复合物的多尺度建模
ACS Omega. 2022 Oct 27;7(44):40279-40292. doi: 10.1021/acsomega.2c05201. eCollection 2022 Nov 8.
3
[Preparation of GH/tPA double transgenic mice and gene expression analysis].[生长激素/组织型纤溶酶原激活剂双转基因小鼠的制备及基因表达分析]
Nan Fang Yi Ke Da Xue Xue Bao. 2021 Nov 20;41(11):1649-1656. doi: 10.12122/j.issn.1673-4254.2021.11.08.

本文引用的文献

1
Latency transition of plasminogen activator inhibitor type 1 is evolutionarily conserved.纤溶酶原激活物抑制剂 1 的潜伏期转移是进化保守的。
Thromb Haemost. 2017 Aug 30;117(9):1688-1699. doi: 10.1160/TH17-02-0102. Epub 2017 Aug 3.
2
Crystal Structure of a Two-domain Fragment of Hepatocyte Growth Factor Activator Inhibitor-1: FUNCTIONAL INTERACTIONS BETWEEN THE KUNITZ-TYPE INHIBITOR DOMAIN-1 AND THE NEIGHBORING POLYCYSTIC KIDNEY DISEASE-LIKE DOMAIN.肝细胞生长因子激活剂抑制剂-1 两结构域片段的晶体结构:Kunitz 型抑制剂结构域-1 与相邻多囊肾病样结构域之间的功能相互作用
J Biol Chem. 2016 Jul 1;291(27):14340-14355. doi: 10.1074/jbc.M115.707240. Epub 2016 May 6.
3
Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1.组织型纤溶酶原激活剂与纤溶酶原激活剂抑制剂-1米氏复合物的晶体结构
J Biol Chem. 2015 Oct 23;290(43):25795-804. doi: 10.1074/jbc.M115.677567. Epub 2015 Aug 31.
4
The EMBL-EBI bioinformatics web and programmatic tools framework.欧洲生物信息学研究所(EMBL-EBI)的生物信息学网络及编程工具框架。
Nucleic Acids Res. 2015 Jul 1;43(W1):W580-4. doi: 10.1093/nar/gkv279. Epub 2015 Apr 6.
5
Sequence co-evolution gives 3D contacts and structures of protein complexes.序列共同进化赋予蛋白质复合物三维接触和结构。
Elife. 2014 Sep 25;3:e03430. doi: 10.7554/eLife.03430.
6
New insights into the structure and function of the plasminogen/plasmin system.对纤溶酶原/纤溶酶系统的结构和功能的新认识。
Curr Opin Struct Biol. 2013 Dec;23(6):836-41. doi: 10.1016/j.sbi.2013.10.006. Epub 2013 Nov 16.
7
Evolutionary biochemistry: revealing the historical and physical causes of protein properties.进化生物化学:揭示蛋白质性质的历史和物理原因。
Nat Rev Genet. 2013 Aug;14(8):559-71. doi: 10.1038/nrg3540.
8
MISTIC: Mutual information server to infer coevolution.MISTIC:互信息服务器推断共进化。
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W8-14. doi: 10.1093/nar/gkt427. Epub 2013 May 28.
9
Protein conformational change delayed by steric hindrance from an N-linked glycan.N-连接聚糖的空间位阻延迟蛋白质构象变化。
J Mol Biol. 2013 Aug 23;425(16):2867-77. doi: 10.1016/j.jmb.2013.05.007. Epub 2013 May 20.
10
Urokinase-type plasminogen activator-like proteases in teleosts lack genuine receptor-binding epidermal growth factor-like domains.硬骨鱼类尿激酶型纤溶酶原激活物样蛋白酶缺乏真正的受体结合表皮生长因子样结构域。
J Biol Chem. 2012 Aug 10;287(33):27526-36. doi: 10.1074/jbc.M112.369207. Epub 2012 Jun 25.